Switch to:
Arena Pharmaceuticals Inc  (NAS:ARNA) EV-to-EBITDA: 2.88 (As of Today)

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Arena Pharmaceuticals Inc's enterprise value is USD 1,817.7 Mil. Arena Pharmaceuticals Inc's EBITDA for the trailing twelve months (TTM) ended in Mar. 2019 was USD 631.7 Mil. Therefore, Arena Pharmaceuticals Inc's EV-to-EBITDA for today is 2.88.

NAS:ARNA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -350.4   Max: 722.4
Current: 2.89

-350.4
722.4

During the past 13 years, the highest EV-to-EBITDA of Arena Pharmaceuticals Inc was 722.40. The lowest was -350.40. And the median was -4.80.

NAS:ARNA's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global industry.

( Industry Median: 18.08 vs. NAS:ARNA: 2.89 )

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today, Arena Pharmaceuticals Inc's stock price is USD 57.90. Arena Pharmaceuticals Inc's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2019 was USD 12.10. Therefore, Arena Pharmaceuticals Inc's PE Ratio for today is 4.79.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Arena Pharmaceuticals Inc Annual Data

Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.12 -3.88 242.75 -13.45 -11.84

Arena Pharmaceuticals Inc Quarterly Data

Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.48 -15.77 -17.39 -11.84 1.97

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Arena Pharmaceuticals Inc Distribution

* The bar in red indicates where Arena Pharmaceuticals Inc's EV-to-EBITDA falls into.



Calculation

Arena Pharmaceuticals Inc's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1817.744/631.747
=2.88

Arena Pharmaceuticals Inc's current Enterprise Value is USD 1,817.7 Mil.
Arena Pharmaceuticals Inc's EBITDA for the trailing twelve months (TTM) ended in Mar. 2019 was -29.432 (Jun. 2018 ) + -31.964 (Sep. 2018 ) + -39.329 (Dec. 2018 ) + 732.472 (Mar. 2019 ) = USD 631.7 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Arena Pharmaceuticals Inc's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=57.90/12.1
=4.79

Arena Pharmaceuticals Inc's share price for today is USD 57.90.
Arena Pharmaceuticals Inc's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2019 was -0.65 (Jun. 2018 ) + -0.7 (Sep. 2018 ) + 1.35 (Dec. 2018 ) + 12.1 (Mar. 2019 ) = USD 12.10.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Related Terms


Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK